8-K

DYNE THERAPEUTICS, INC.

Date: May 22, 2024

/s/ John G. Cox

John G. Cox

President and Chief Executive Officer

0001193125-24-144470.txt : 20240522 0001193125-24-144470.hdr.sgml : 20240522 20240522075902 ACCESSION NUMBER: 0001193125-24-144470 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 20 CONFORMED PERIOD OF REPORT: 20240521 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240522 DATE AS OF CHANGE: 20240522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24971659 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d812513d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 21, 2024

Dyne Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware	001-39509	36-4883909
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)


1560 Trapelo Road
Waltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 786-8230

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, $0.0001 par value per share	DYN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry Into a Material Definitive Agreement.

On May 21, 2024, Dyne Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 10,500,000 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). All of the Underwritten Shares are being sold by the Company. The public offering price of the Underwritten Shares is $31.00 per share, and the Underwriters have agreed to purchase the Underwritten Shares from the Company pursuant to the Underwriting Agreement at a price of $29.14 per share. Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days from the date of the Underwriting Agreement, to purchase up to an additional 1,575,000 shares of Common Stock (the “Option Shares” and together with the Underwritten Shares, the “Shares”) at the public offering price less the underwriting discounts and commissions.

The Company estimates that the net proceeds from the Offering will be approximately $305.4 million, or approximately $351.4 million if the Underwriters exercise in full their option to purchase the Option Shares, in each case, after deducting underwriting discounts and commissions and estimated offering expenses.

The Shares will be issued pursuant to a prospectus supplement dated May 21, 2024, and an accompanying base prospectus that form a part of the registration statement on Form S-3 that the Company filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2024 (File No. 333-277655), which was automatically effective upon filing. The closing of the Offering is expected to take place on or about May 24, 2024, subject to the satisfaction of customary closing conditions.

The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.

A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit.

A copy of the legal opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP relating to the Shares is attached as Exhibit 5.1 hereto.

Item 8.01. Other Events.

Pricing of Public Offering

The full text of the press release issued on May 21, 2024, announcing the pricing of the Offering is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Cash Runway

The Company believes that the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, will enable the Company to fund its operating expenses and capital expenditure requirements at least into the second half of 2026. The Company has based its estimates on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including the anticipated net proceeds from the Offering, the anticipated closing date of the Offering and the Company’s anticipated cash runway, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties related to market conditions and the satisfaction of customary closing conditions related to the Offering, uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and the Company’s ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; uncertainties as to the U.S. Food and Drug Administration’s and other regulatory authorities’ interpretation of the data from the Company’s clinical trials and acceptance of the Company’s clinical programs and the regulatory approval process; whether the Company’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties discussed in the “Risk Factors” section contained in the preliminary prospectus supplement related to the Offering filed with the SEC on May 20, 2024, and the Company’s quarterly and annual reports on file with the SEC. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits


Exhibit No.		Description

1.1		Underwriting Agreement, dated May 21, 2024, by and among the Company and Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters named therein.

5.1		Opinion of Wilmer Cutler Pickering Hale and Dorr LLP

23.1		Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1 above)

99.1		Press Release of Dyne Therapeutics, Inc., dated May 21, 2024

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-1.1 2 d812513dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

UNDERWRITING AGREEMENT

DYNE THERAPEUTICS, INC.

10,500,000 Shares of Common Stock, par value $0.0001 per share

Underwriting Agreement

May 21, 2024

Morgan Stanley & Co. LLC

Jefferies LLC

Stifel, Nicolaus & Company, Incorporated

Guggenheim Securities, LLC

As Representatives of the

several Underwriters listed

in Schedule 1 hereto

c/o Morgan Stanley & Co. LLC

1585 Broadway

New York, New York 10036

c/o Jefferies LLC

520 Madison Avenue

New York, New York 10022

c/o Stifel, Nicolaus & Company, Incorporated

787 7th Avenue, 32nd Floor

New York, New York 10019

c/o Guggenheim Securities, LLC

330 Madison Avenue

New York, New York 10017

Ladies and Gentlemen:

Dyne Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 10,500,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,575,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.

The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows:

1. Registration Statement. The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Securities Act”), an “automatic shelf” registration statement on Form S-3 (File No. 333-277655), including a base prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (“Rule 430 Information”), is referred to herein as the “Registration Statement”; and as used herein, the term “Preliminary Prospectus” means the base prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term “Prospectus” means the prospectus in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the “Rule 462 Registration Statement”), then any reference herein to the term “Registration Statement” shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this “Agreement”) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to “amend”, “amendment” or “supplement” with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Exchange Act”) that are deemed to be incorporated by reference therein.

At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated May 20, 2024 and each “free-writing prospectus” (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto.

“Applicable Time” means 6:30 P.M. New York City time, on May 21, 2024.

2. Purchase of the Shares.

(a) The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this underwriting agreement (this “Agreement”), and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $29.14 (the “Purchase Price”) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter’s name in Schedule 1 hereto.

In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares.

If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set forth in Section 10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representatives in their sole discretion shall make.

The Underwriters may exercise the option to purchase Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section 10 hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified therein.

(b) The Company understands that the Underwriters intend to make a public offering of the Shares and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter.

(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the Representatives in the case of the Underwritten Shares, at the offices of Cooley LLP, counsel for the Underwriters, at 55 Hudson Yards, New York, NY 10001 at 10:00 A.M. New York City time on May 24, 2024, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the Representatives in the written notice of the Underwriters’ election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the “Closing Date”, and the time and date for such payment for the Option Shares, if other than the Closing Date, is herein referred to as the “Additional Closing Date”.

Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date registered in such names and in such denominations as the Representatives shall request in writing not later than two full business days prior to the Closing Date or the Additional Closing Date (or not later than the standard settlement cycle), as the case may be, with any transfer taxes payable in connection with the sale of such Shares duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct.

(d) The Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm’s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.

3. Representations and Warranties of the Company. The Company represents and warrants to each Underwriter that:

(a) Preliminary Prospectus. No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.

(b) Pricing Disclosure Package. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in the Prospectus has been omitted therefrom.

(c) Issuer Free Writing Prospectus. Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any “written communication” (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i) below) an “Issuer Free Writing Prospectus”) other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii) the documents listed on Annex A hereto, each electronic road show and any other written communications approved in advance by the Representatives. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433 under the Securities Act) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with all other Issuer Free Writing Prospectuses and the Preliminary Prospectus accompanying, or delivered prior to delivery of, or filed prior to the first use of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.

(d) Emerging Growth Company. From the time of initial confidential submission of the registration statement relating to the Company’s initial public offering to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communication (as defined below) undertaken in reliance on Section 5(d) of the Securities Act) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”). “Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on either Section 5(d) of, or Rule 163B under, the Securities Act.

(e) Testing-the-Waters Materials. The Company (i) has not alone engaged in any Testing-the-Waters Communications in connection with the offering to which this Agreement relates and (ii) has not authorized anyone to engage in Testing-the-Waters Communications in connection with the offering to which this Agreement relates. The Company has not distributed or approved for distribution any Written Testing-the-Waters Communications in connection with the offering of the Shares. “Written Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act.”

(f) Registration Statement and Prospectus. The Registration Statement is an “automatic shelf registration statement” as defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no notice of objection of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.

(g) Incorporated Documents. The documents incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(h) Financial Statements. The financial statements (including the related notes thereto) of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company as of the dates indicated and the results of its operations and the changes in its cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) applied on a consistent basis throughout the periods covered thereby, except in the case of any unaudited financial statements, which are subject to normal year-end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby; all disclosures included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. The terms “subsidiary” and “subsidiaries” as used herein shall refer to Dyne Therapeutics Securities Corporation.

(i) No Material Adverse Change. Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants or vesting of restricted stock units described as

outstanding in, and the grant of options and other awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders’ equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(j) Organization and Good Standing. The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing under the laws of its jurisdiction of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold its properties and to conduct the business in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial position, stockholders’ equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a “Material Adverse Effect”). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiary listed in Exhibit 21.1 to the Company’s most recent Annual Report on Form 10-K.

(k) Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or

any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options that have not been duly waived or satisfied; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.

(l) Stock Options. With respect to the stock options (the “Stock Options”) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the “Company Stock Plans”), (i) each Stock Option intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the “Grant Date”) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and, to the knowledge of the Company (other than with respect to due execution and delivery by the Company), the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in accordance with the terms of the applicable Company Stock Plan and all applicable laws and regulatory rules and requirements, and (iv) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company’s filings with the Commission in accordance with the Exchange Act, as applicable, and all other applicable laws. Each Company Stock Plan is accurately described in all material respects in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(m) Due Authorization. The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.

(n) Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(o) The Shares. The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied.

(p) No Violation or Default. Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(q) No Conflicts. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares by the Company and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(r) No Consents Required. No consent, filing, approval, authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation by the Company of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (“FINRA”) or the Nasdaq Global Select Market (the “Nasdaq Market”) and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters.

(s) Legal Proceedings. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (“Actions”) pending to which the Company or any of its subsidiaries is or may reasonably be expected to become a party or to which any property of the Company or any of its subsidiaries is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i) there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed or incorporated by reference as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed or incorporated by reference as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(t) Independent Accountants. Deloitte & Touche LLP, which has certified certain financial statements of the Company, is an independent registered public accounting firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.

(u) Title to Real and Personal Property. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii) would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(v) Intellectual Property. The Company and its subsidiaries own or possess valid and enforceable licensed rights to use, all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, trade dress, designs, data, database rights, Internet domain names, copyrights, works of authorship, licenses, proprietary information and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or

confidential information, systems or procedures) (collectively, “Intellectual Property”) necessary for the conduct of their respective businesses as currently conducted or as proposed to be conducted, and, to the knowledge of the Company and its subsidiaries, the conduct of their respective business does not and will not infringe, misappropriate or otherwise conflict with in any material respect any valid and enforceable intellectual property rights of others. Neither the Intellectual Property of the Company nor any of its subsidiaries has been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company and its subsidiaries are unaware of any facts which would form a reasonable basis for any such adjudication. Neither the Company nor any of its subsidiaries has received any notice of any material claim of infringement, misappropriation or conflict with any intellectual property rights of another, and neither the Company nor any of its subsidiaries is aware of any facts which would form a reasonable basis for any such notice or claim. Neither the Company nor any of its subsidiaries has received any notice of any claim, or is otherwise unaware, of any facts or circumstances which would render any Intellectual Property of the Company or any of its subsidiaries invalid or inadequate to protect the interest of the Company or any of its subsidiaries. To the Company’s and any of its subsidiaries’ knowledge: (i) there are no third parties who have rights to any Intellectual Property of the Company or any of its subsidiaries, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus as owned by or licensed to the Company; and (ii) there is no infringement by third parties of any Intellectual Property of the Company or any of its subsidiaries. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no pending or, to the knowledge of the Company and its subsidiaries, existing threatened action, suit, proceeding or claim by others: (A) challenging the Company’s or any of its subsidiaries’ rights in or to any Intellectual Property of the Company or any of its subsidiaries, and the Company and its subsidiaries are unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity, enforceability or scope of any Intellectual Property of the Company or any of its subsidiaries, and the Company and its subsidiaries are unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company or any of its subsidiaries infringes, misappropriates, or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Pricing Disclosure Package and the Prospectus as under development, infringe, misappropriate, or otherwise violate, any intellectual property rights of others, and neither the Company nor any of its subsidiaries is aware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and each of its subsidiaries has complied with the terms of each agreement pursuant to which Intellectual Property of the Company or any of its subsidiaries has been licensed to the Company or any of its subsidiaries, and all such agreements are in full force and effect. To the Company’s and any of its subsidiaries’ knowledge there is no prior art that may render any patent within the Intellectual Property of the Company or any of its subsidiaries invalid or that may render any patent application within the

Intellectual Property of the Company or any of its subsidiaries unpatentable that has not been appropriately disclosed to the U.S. Patent and Trademark Office. To the Company’s and any of its subsidiaries’ knowledge, there is no patent or published patent application, in the U.S. or other jurisdiction, which, in the case of a patent, contains valid claims, or in the case of a published patent application contains patentable claims, that dominate or may dominate any of the Company’s or any of its subsidiaries’ Intellectual Property described in the Preliminary Prospectus and Prospectus as being owned by or licensed to the Company or any of its subsidiaries or that interferes with the issued or pending claims of any of the Company’s or any of its subsidiaries’ Intellectual Property. To the Company’s and any of its subsidiaries’ knowledge, the patents included in the Intellectual Property of the Company or any of its subsidiaries are subsisting and have not lapsed and the patent applications in the Intellectual Property of the Company or any of its subsidiaries are subsisting and have not been abandoned. To the Company’s and any of its subsidiaries’ knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property of the Company or any of its subsidiaries. The Company and any of its subsidiaries have taken all reasonable steps to protect, maintain and safeguard the Intellectual Property of the Company or any of its subsidiaries, including the execution of appropriate nondisclosure, confidentiality and invention assignment agreements and invention assignments with its employees, and, to the knowledge of the Company and any of its subsidiaries, no employee of the Company or any of its subsidiaries is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company or any of its subsidiaries. To the Company’s and any of its subsidiaries’ knowledge, the duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property of the Company or any of its subsidiaries have been complied with; and in all foreign offices having similar requirements, all such requirements have been complied with. None of the Company owned Intellectual Property, including Intellectual Property owned by any of the Company’s subsidiaries, or technology (including information technology and outsourced arrangements) employed by the Company or any of its subsidiaries has been obtained or is being used by the Company or any of its subsidiaries in violation of any contractual obligation binding on the Company or any of its subsidiaries, or any of the Company’s or any of its subsidiaries’ officers, directors or employees or otherwise in violation of the rights of any persons. The product candidates described in the Registration Statement, the Pricing Disclosure Package and the Prospectus as under development by the Company or any of its subsidiaries fall within the scope of the claims of one or more patents or patent applications owned by, or exclusively licensed to, the Company or any of its subsidiaries.

(w) Data Privacy and Security Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable data privacy and security laws and regulations, including, without limitation, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) as amended by the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”), the California Consumer Privacy Act of 2018, as amended (“CCPA”), the Federal Trade Commission Act and state consumer protection laws, the European Union General Data Protection Regulation (“EU GDPR”) (EU 2016/679), and the EU GDPR as it forms part of United Kingdom law (“UK GDPR”) (collectively, the “Privacy Laws”). “Personal Data” means (i) any information which would qualify as “personally identifying information,” “personal data, “personal information,” or similar term under Privacy Laws; or (ii) any information that relates to an identified or identifiable natural person, or that is reasonably capable of being used to identify, contact, or precisely locate a natural person or a particular computing system or device. Neither the Company nor any of its subsidiaries (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any Privacy Law, or has knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation or threatened investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.

(x) No Complaints. To the knowledge of the Company or any of its subsidiaries, there is no complaint to or audit, proceeding, investigation (formal or informal) or claim currently pending against the Company or any of its subsidiaries or customers (specific to the customer’s use of the products or services of the Company) by the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained therein (“HHS”), or any similar authority in any jurisdiction other than the United States or any other governmental entity, or by any person in respect of the collection, use or disclosure of Personal Data by the Company or any of its subsidiaries, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened.

(y) FDA Compliance. The Company and each of its subsidiaries: (A) is and at all times has been in material compliance with all statutes, rules or regulations of the FDA and other comparable governmental entities with jurisdiction over the Company or any of its subsidiaries that are applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company or any of its subsidiaries (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other written correspondence or notice from the FDA or any governmental entity alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company or any of its subsidiaries is not in material violation of any term of any such Authorizations; (D) has not received notice of

any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any governmental entity or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any governmental entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received written notice that the FDA or any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any governmental entity is considering such action; and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).

(z) Tests and Clinical Trials. The studies, tests and clinical trials conducted by or, to the Company’s or any of its subsidiaries’ knowledge, on behalf of the Company or any of its subsidiaries were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and current Good Clinical Practices and Good Laboratory Practices and any applicable rules, regulations and policies of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s or any of its subsidiaries’ knowledge, accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and each of its subsidiaries is not aware of any studies, tests or trials, the results of which the Company or any of its subsidiaries believes reasonably call into question in any material respect the study, test, or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any of the studies, tests or clinical trials conducted by or on behalf of the Company or any of its subsidiaries, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

(aa) Compliance with Health Care Laws. The Company and its subsidiaries are, and at all times have been, in compliance in all material respects with all Health Care Laws to the extent applicable to the Company or any of its subsidiaries or their respective businesses. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Statements Law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286, 287, 1035, and 1349, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section 1320d et seq.), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusions law (42 U.S.C. Section 1320a-7), laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the HITECH Act, (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or any of its subsidiaries, and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company, any of its subsidiaries, nor any of their respective officers, directors, employees and, to the knowledge of the Company and each of its subsidiaries, any of their respective agents have engaged in activities which are, as applicable, cause for liability under a Health Care Law. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company’s or any of its subsidiaries’ knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. None of the Company nor any of its subsidiaries nor their respective employees, officers, directors, or, to the knowledge of the Company or any of its subsidiaries, their respective agents is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority related to activities conducted by or on behalf of the Company or any of its subsidiaries. Additionally, none of the Company nor any of its subsidiaries nor their respective employees, officers, directors, or, to the knowledge of the Company or any of its subsidiaries, their respective agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company or any of its subsidiaries, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.

(bb) No Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package.

(cc) Investment Company Act. The Company is not and, immediately after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an “investment company” or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment Company Act”).

(dd) Taxes. The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid (except for taxes being contested in good faith) or filed (taking into account any duly requested extension thereof) through the date hereof, except in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets that would reasonably be expected to have a Material Adverse Effect.

(ee) Licenses and Permits. The Company and its subsidiaries possess all licenses, sub-licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, sub-license, certificate, permit or authorization or has any reason to believe that any such license, sub-license, certificate, permit or authorization will not be renewed in the ordinary course except where such revocation, modification or nonrenewal would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(ff) No Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries’ principal suppliers, contractors or customers, except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party.

(gg) Certain Environmental Matters. (i) The Company and its subsidiaries (x) are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z) have not received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or any of its subsidiaries, except in the case of each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in each of the Pricing Disclosure Package and the Prospectus, (x) there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a Material Adverse Effect, and (z) none of the Company or its subsidiaries anticipate material capital expenditures relating to any Environmental Laws.

(hh) Hazardous Materials. There has been no storage, generation, transportation, use, handling, treatment, Release or threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or could reasonably be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or leased by the Company or any of its subsidiaries, or at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any liability under any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. “Hazardous Materials” means any material, chemical, substance ,waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can

give rise to liability under any Environmental Law. “Release” means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into from or through any building or structure.

(ii) Compliance with ERISA. (i) Each employee benefit plan, within the meaning of, and subject to, Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Code) would have any liability (each, a “Plan”) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be, in “at risk status” (within the meaning of Section 303(i) of ERISA) and no Plan that is a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA is in “endangered status” or “critical status” (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan that is required to be funded exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no “reportable event” (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and to the knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA); and (ix) none of the following events has occurred or is reasonably likely to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company’s and its Controlled Group affiliates’ most recently completed fiscal year; or (B) a material increase in the Company and its subsidiaries’ “accumulated post-retirement benefit obligations” (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such obligations in the Company and its subsidiaries’ most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect.

(jj) Disclosure Controls. The Company and its subsidiaries have established a system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.

(kk) Accounting Controls. The Company and its subsidiaries maintain systems of “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that have been designed to comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, its principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) as applicable, the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Based on the Company’s most recent evaluation of its internal controls over financial reporting pursuant to Rule 13a-15(c) of the Exchange Act, there are no material weaknesses in the Company’s internal controls over financial reporting. The Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.

(ll) eXtensible Business Reporting Language. The interactive data in eXtensible Business reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

(mm) Insurance. The Company and its subsidiaries have insurance covering its properties, operations, personnel and business, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.

(nn) Cybersecurity; Data Protection. The Company and its subsidiaries’ information technology assets and equipment, including, without limitation, those owned, licensed or otherwise used (excluding any public networks), such as its data communications lines, computers, systems, networks, hardware, servers, software, websites, applications, and databases (collectively, “IT Systems”) are (i) adequate for, and operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted and as proposed to be conducted as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and (ii) free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants, except in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have at all times implemented and maintained all reasonably necessary controls, policies, procedures, and safeguards consistent with industry standards and practices for similarly situated companies to maintain and protect the integrity, availability, privacy, continuous operation, redundancy and security of all IT Systems and data (including all Personal Data, and other sensitive, confidential or regulated data) (“Company Data”) used in connection with their respective businesses, and there have been no breaches, violations, outages, compromises, or unlawful or unauthorized acquisitions of, disclosures of, uses of or accesses to the same, except in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries are presently and, at all times, have been in compliance with all (i) applicable laws, statutes, judgments, orders, rules and regulations of any court, arbitrator, governmental or regulatory authority; and (ii) internal policies and contractual obligations, each (i) and (ii) relating to the privacy and security of IT Systems and Company Data.

(oo) No Unlawful Payments. Neither the Company nor any of its subsidiaries nor any director or officer of the Company or any of its subsidiaries nor, to the knowledge of the Company, any employee of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, payment, promise or authorization or approval of any payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any foreign or domestic government or regulatory official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office in order to influence official action in violation of any applicable anti-corruption laws, or to any person in violation of any applicable anti-corruption laws; (iii) violated or is in violation of any applicable anti-corruption laws, including any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have conducted their businesses in compliance with applicable anti-corruption laws and have instituted, maintained and enforced, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.

(pp) Compliance with Anti-Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including but not limited to those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency with respect to any jurisdiction where the Company or any of its subsidiaries conducts business (collectively, the “Anti-Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(qq) No Conflicts with Sanctions Laws. Neither the Company nor any of its subsidiaries, directors or officers, nor, to the knowledge of the Company, any employees of the Company or any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions

administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a “specially designated national” or “blocked person”), the United Nations Security Council, the European Union, His Majesty’s Treasury or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, Syria, the so-called Luhansk People’s Republic, the so-called Donetsk People’s Republic and the non-government controlled areas of Zaporizhzhia and Kherson regions of Ukraine (each, a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any direct or indirect dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.

(rr) No Restrictions on Subsidiaries. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company.

(ss) No Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Shares.

(tt) No Registration Rights. No person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares, except for any such rights that have been waived.

(uu) No Stabilization. Neither the Company nor any of its subsidiaries nor, to the Company’s knowledge, any of its affiliates has taken, directly or indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares.

(vv) Margin Rules. Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.

(ww) Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

(xx) Statistical and Market Data. Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.

(yy) FINRA Matters. The Company meets the definition of the term “experienced issuer” specified in FINRA Rule 5110(j)(6).

(zz) Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company’s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.

(aaa) Status under the Securities Act. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an “ineligible issuer,” and was and is a “well-known seasoned issuer”, in each case as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date.

(bbb) No Ratings. There are (and prior to the Closing Date, will be) no debt securities, convertible securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a “nationally recognized statistical rating organization”, as such term is defined in Section 3(a)(62) under the Exchange Act.

4. Further Agreements of the Company. The Company covenants and agrees with each Underwriter that:

(a) Required Filings. The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request.

(b) Delivery of Copies. Upon written request of the Representatives, the Company will deliver, without charge, (i) to the Representatives, three signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii) to each Underwriter (A) a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term “Prospectus Delivery Period” means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer.

(c) Amendments or Supplements, Issuer Free Writing Prospectuses. Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus relating to the Shares, whether before or after the time that the Registration Statement becomes effective, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement relating to the Shares to which the Representatives reasonably object in a timely manner.

(d) Notice to the Representatives. The Company will advise the Representatives promptly, and confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii) when any amendment to the Registration Statement related to the Shares has been filed or becomes effective; (iii) when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication or any amendment to the Prospectus has been filed or distributed; (iv) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any Testing-the-Waters Communication; (v) of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written Testing-the-Waters Communication or, to the knowledge of the Company, the initiation or threatening of any proceeding for that purpose or pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication is delivered to a purchaser, not misleading; and (vii) of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or, to the knowledge of the Company, the initiation or threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written Testing-the-Waters Communication or suspending any such qualification of the Shares and, if any such order is issued, will use its reasonable best efforts to obtain as soon as possible the withdrawal thereof.

(e) Ongoing Compliance. (1) If during the Prospectus Delivery Period (i) any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the

circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2) if at any time prior to the Closing Date or any Additional Closing Date (i) any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements (or any document to be filed with the Commission and incorporated by reference therein) to the Pricing Disclosure Package as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.

(f) Blue Sky Compliance. The Company will use commercially reasonable best efforts, with the Underwriters’ cooperation, if necessary, to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will use commercially reasonable best efforts, with the Underwriters’ cooperation, if necessary, to continue such qualifications in effect so long as required for distribution of the Shares; provided that the Company shall not be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.

(g) Earning Statement. The Company will make generally available to its security holders and the Representatives as soon as reasonably practicable an earning statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the “effective date” (as defined in Rule 158) of the Registration Statement, it being understood and agreed that such earning statement shall be deemed to have been made available by the Company if the Company is in compliance with its reporting obligations pursuant to the Exchange Act, if such compliance satisfies the conditions of Rule 158 and if such earnings statement is deemed to have been made available on the Commission’s Electronic Data Gathering, Analysis, and Retrieval system (“EDGAR”).

(h) Clear Market. For a period of 60 days after the date of the Prospectus, the Company will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or

file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention to undertake any of the foregoing, or (ii) enter into any swap, hedging or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of Morgan Stanley & Co. LLC and Jefferies LLC, other than the Shares to be sold hereunder.

The restrictions described above do not apply to (i) the issuance of shares of Stock or securities convertible into or exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of RSUs (including net settlement), in each case outstanding on the date of this Agreement and described in the Prospectus; (ii) grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company’s employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described in the Prospectus, provided that the Company shall cause each newly appointed director or executive officer that is a recipient of such shares of Stock or other securities of the Company to enter into a lock-up agreement with the Underwriters substantially in the form of Exhibit A hereto for the remainder of the 60 day lock-up period; (iii) the filing of any registration statement on Form S-8 relating to securities granted or to be granted pursuant to any plan in effect as of the Closing Date and described in the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction; (iv) shares of Stock or other securities issued in connection with a transaction with an unaffiliated third party that includes a debt financing or a bona fide commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any acquisition of assets or acquisition of not less than a majority or controlling portion of the equity of another entity, provided that (x) the aggregate number of shares issued pursuant to this clause (iv) shall not exceed five percent (5%) of the total number of outstanding shares of Stock immediately following the issuance and sale of the Shares pursuant hereto and (y) the recipient of any such shares of Stock and securities issued pursuant to this clause (iv) during the 60-day restricted period described above shall enter into an agreement substantially in the form of Exhibit A hereto for the remainder of the 60 day lock-up period.

(i) Use of Proceeds. The Company will apply the net proceeds from the sale of the Shares in all material respects as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading “Use of Proceeds”.

(j) No Stabilization. Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock.

(k) Exchange Listing. The Company will use its reasonable best efforts to list the Shares on the Nasdaq Market.

(l) Reports. For a period of three years from the effective date of the Registration Statement (provided that the Company remains subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act), the Company will furnish to the Representatives, as soon as they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; provided the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed or furnished on EDGAR; provided further that no additional information shall be required if the disclosure of such additional information would result in a violation of Regulation FD.

(m) Record Retention. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act for the time period required by such rule.

(n) Shelf Renewal. If immediately prior to the third anniversary (the “Renewal Deadline”) of the initial effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration statement relating to the Shares, in a form satisfactory to the Representative. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done so, file a new shelf registration statement relating to the Shares, in a form satisfactory to the Representative, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be.

(o) Emerging Growth Company. The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of Shares within the meaning of the Securities Act and (ii) completion of the 60-day restricted period referred to in Section 4(h) hereof.

5. Certain Agreements of the Underwriters. Each Underwriter hereby represents and agrees that:

(a) It has not used, authorized use of, referred to or participated in the planning for use of, and will not use, authorize use of, refer to or participate in the planning for use of, any “free writing prospectus”, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i) a free writing prospectus that contains no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section 3(c) or Section 4(c) above (including any electronic road show approved by the Company in advance in writing), or (iii) any free writing prospectus prepared by such underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i) or (iii), an “Underwriter Free Writing Prospectus”).

(b) It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms of the offering of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission.

(c) It is not subject to any pending proceeding under Section 8A of the Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).

6. Conditions of Underwriters’ Obligations. The obligation of each Underwriter to purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions:

(a) Registration Compliance; No Stop Order. No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section 8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section 4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives.

(b) Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be.

(c) No Material Adverse Change. No event or condition of a type described in Section 3(i) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.

(d) Officer’s Certificate. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the principal financial officer or principal accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives (i) confirming that such officers have reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations of the Company set forth in Sections 3(b) and 3(c) hereof are true and correct, (ii) confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii) to the effect set forth in paragraphs (a) and (c) above.

(e) Comfort Letters. (i) On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, Deloitte & Touche LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a “cut-off” date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be.

(f) Opinion and 10b-5 Statement of Counsel for the Company. Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and negative assurance statement, dated the Closing Date or the Additional Closing Date, as the case may be, addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives and as previously agreed.

(g) Opinion of Intellectual Property Counsel for the Company. Wolf, Greenfield & Sacks, P.C., intellectual property counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives and as previously agreed.

(h) Opinion and 10b-5 Statement of Counsel for the Underwriters. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and 10b-5 statement, addressed to the Underwriters, of Cooley LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.

(i) No Legal Impediment to Issuance and Sale. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares.

(j) Good Standing. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their respective good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions.

(k) Exchange Listing. The Company shall have submitted a Listing of Additional Shares Notification Form to the Nasdaq Market with respect to the Shares.

(l) Lock-up Agreements. The “lock-up” agreements, each substantially in the form of Exhibit A hereto, between you and the executive officers and directors of the Company relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date or the Additional Closing Date, as the case may be.

(m) Additional Documents. On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.

All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.

7. Indemnification and Contribution.

(a) Indemnification of the Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable and documented legal fees and other reasonable and documented expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii) any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written Testing-the-Waters Communication, any road show as defined in Rule 433(h) under the Securities Act (a “road show”) or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in paragraph (b) below.

(b) Indemnification of the Company. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing

Prospectus, any Written Testing-the-Waters Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the third paragraph of text under the caption “Underwriters” concerning the terms of the offering and the thirteenth paragraph of text under the caption “Underwriters” concerning stabilization.

(c) Notice and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section 7, such person (the “Indemnified Person”) shall promptly notify the person against whom such indemnification may be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of this Section 7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided, further, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section 7. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees and expenses in such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such reasonable and documented fees and expenses shall be paid or reimbursed as they are incurred upon receipt from the Indemnified Person of a written request for payment thereof accompanied by a written statement with reasonable supporting detail of such fees and expenses. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by Morgan Stanley & Co. LLC and Jefferies LLC and any such separate firm for the Company, its directors, its officers who signed the Registration

Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable and documented fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into (A) more than 60 days after receipt by the Indemnifying Person of such request and (B) more than 30 days after receipt by the Indemnifying Person of the proposed terms of such settlement and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.

(d) Contribution. If the indemnification provided for in paragraphs (a) or (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from the offering of the Shares or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

(e) Limitation on Liability. The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to paragraph (d) above were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be deemed to include, subject to the limitations set forth above, any reasonable and documented legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d) and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to paragraphs (d) and (e) are several in proportion to their respective purchase obligations hereunder and not joint.

(f) Non-Exclusive Remedies. The remedies provided for in this Section 7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity.

8. Effectiveness of Agreement. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.

9. Termination. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i) trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.

10. Defaulting Underwriter.

(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriters to purchase such Shares on such terms. If other persons become obligated or agree to purchase the Shares of a defaulting Underwriter, either the non-defaulting Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term “Underwriter” includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 10, purchases Shares that a defaulting Underwriter agreed but failed to purchase.

(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, does not exceed one-eleventh of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter’s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made.

(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b) above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the non-defaulting Underwriters. Any termination of this Agreement pursuant to this Section 10 shall be without liability on the part of the Company, except that the Company and the Underwriters will continue to be liable for the payment of expenses as set forth in Section 11 hereof and except that the provisions of Section 7 hereof shall not terminate and shall remain in effect.

(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any non-defaulting Underwriter for damages caused by its default.

11. Payment of Expenses.

(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the fees and expenses of the Company’s counsel and independent accountants; (iv) the reasonable fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum and any “Canadian wrapper” (including the related fees and expenses of counsel for the Underwriters, not to exceed $5,000); (v) the cost of preparing stock certificates; (vi) the costs and charges of any transfer agent and any registrar; (vii) all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA (including the reasonable and documented fees and expenses of counsel for the Underwriters, not to exceed $25,000); (viii) all expenses incurred by the Company in connection with any “road show” presentation to potential investors, provided that, (A) the Company and the Underwriters will each bear 50% of the cost of any aircraft used and (B) the Company and the Underwriters will each pay their own costs associated with hotel accommodations; and (ix) all expenses and application fees related to the listing of the Shares on the Nasdaq Market.

(b) If (i) this Agreement is terminated pursuant to Section 9, (ii) the Company for any reason fails to tender the Shares for delivery to the Underwriters (other than by reason of a default by any Underwriter) or (iii) the Underwriters decline to purchase the Shares for any reason permitted under this Agreement (other than following termination of this Agreement pursuant to clauses (i), (iii) or (iv) of Section 9), the Company agrees to reimburse the Underwriters for all reasonable and documented out-of-pocket costs and expenses (including the reasonable and documented fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, the Company will not pay or reimburse pursuant to this Section 11 any costs, fees or expenses incurred by any underwriter that defaults on its obligations to purchase the Shares or following termination of this Agreement by the Underwriters pursuant to clauses (i), (iii) or (iv) of Section 9.

12. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section 7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such purchase.

13. Survival. The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons or affiliates referred to in Section 7 hereof.

14. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day on which banks are permitted or required to be closed in New York City; and (c) the term “subsidiary” has the meaning set forth in Rule 405 under the Securities Act.

15. Compliance with USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.

16. Miscellaneous.

(a) Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o Morgan Stanley & Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; c/o Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: General Counsel; c/o Stifel, Nicolaus & Company, Incorporated, 787 7th Avenue, 32nd Floor, New York, New York 10019, Attention: Equity Capital Markets; and c/o Guggenheim Securities, LLC, 330 Madison Avenue, New York, New York 10017, Attention Head of Equity Capital Markets. Notices to the Company shall be given to it at 1560 Trapelo Road Waltham, Massachusetts, 02451, (fax: (781) 786-8866); Attention: Chief Executive Officer.

(b) Submission to Jurisdiction. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the jurisdiction of which Company is subject by a suit upon such judgment.

(c) Governing Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York.

(d) Waiver of Jury Trial. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

(e) Recognition of the U.S. Special Resolution Regimes.

(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

As used in this Section 16(e):

“BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).

“Covered Entity” means any of the following:

(i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);

(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or

(iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

“Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.

“U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

(f) Counterparts. This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original but all such counterparts shall together constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

(g) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.

(h) Headings. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.

(i) Integration. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof.

[Signature Page Follows]

If the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space provided below.


Very truly yours,

DYNE THERAPEUTICS, INC.

By:		/s/ John G. Cox
		Name: John G. Cox
		Title: President and Chief Executive Officer


Accepted: As of the date first written above

MORGAN STANLEY & CO. LLC
JEFFERIES LLC
STIFEL, NICOLAUS & COMPANY, INCORPORATED
GUGGENHEIM SECURITIES, LLC

For themselves and on behalf of the several Underwriters listed in Schedule 1 hereto.

MORGAN STANLEY & CO. LLC

By:		/s/ Kalli Dircks
		Authorized Signatory

JEFFERIES LLC

By:		/s/ Kevin Sheridan
		Authorized Signatory

STIFEL, NICOLAUS & COMPANY, INCORPORATED

By:		/s/ Nicholas Oust
		Authorized Signatory

GUGGENHEIM SECURITIES, LLC

By:		/s/ Geoffrey Goodman
		Authorized Signatory

Schedule 1


Underwriter	Number of Shares
Morgan Stanley & Co. LLC		4,147,500
Jefferies LLC		2,730,000
Stifel, Nicolaus & Company, Incorporated		1,522,500
Guggenheim Securities, LLC		1,260,000
Oppenheimer & Co. Inc.		420,000
Raymond James & Associates, Inc.		420,000

Total		10,500,000

Sch.-1

Annex A

a.	Pricing Disclosure Package

None.

b.	Pricing Information Provided Orally by Underwriters

The number of Underwritten Shares purchased by the Underwriters is 10,500,000.

The number of Option Shares is 1,575,000.

The public offering price per share is $31.00.

A-1

Annex B

Written Testing-the-Waters Communications

None.

B-1

Exhibit A

Form of Lock-Up Agreement

May , 2024

MORGAN STANLEY & CO. LLC

JEFFERIES LLC

STIFEL, NICOLAUS & COMPANY, INCORPORATED

GUGGENHEIM SECURITIES, LLC

As Representatives of

the several Underwriters listed in

Schedule 1 to the Underwriting

Agreement referred to below

c/o Morgan Stanley & Co. LLC

1585 Broadway

New York, New York 10036

c/o Jefferies LLC

520 Madison Avenue

New York, New York 10022

c/o Stifel, Nicolaus & Company, Incorporated

787 7th Avenue, 32nd Floor

New York, New York 10019

c/o Guggenheim Securities, LLC

330 Madison Avenue

New York, New York 10017

Re: Dyne Therapeutics, Inc. — Public Offering

Ladies and Gentlemen:

The undersigned understands that you, as representatives (the “Representatives”) of the several Underwriters, propose to enter into an underwriting agreement (the “Underwriting Agreement”) with Dyne Therapeutics, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the “Underwriters”), of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Securities”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.

In consideration of the Underwriters’ agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of Morgan Stanley & Co. LLC and Jefferies LLC on behalf of the Underwriters, the undersigned will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this “Letter

Agreement”) and ending at the close of business 60 days after the date of the final prospectus supplement relating to the Public Offering (the “Prospectus”) (such period, the “Restricted Period”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Stock, the “Lock-Up Securities”), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise, (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities, or (4) publicly disclose the intention to do any of the foregoing.

Notwithstanding the foregoing, the undersigned may:

(a) transfer or dispose of the undersigned’s Lock-Up Securities:

(i) as a bona fide gift or gifts, or for bona fide estate planning purposes,

(ii) by will, other testamentary document or intestacy,

(iii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, “immediate family” shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),

(iv) to a corporation, partnership, limited liability company, trust or other entity of which the undersigned and/or one or more members of the immediate family of the undersigned are, directly or indirectly, the legal and beneficial owner of all of the outstanding equity securities or similar interests,

(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above,

(vi) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a distribution or other transfer to general or limited partners, members or shareholders of, or other holders of equity in, the undersigned,

(vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree, separation agreement or court order,

(viii) to the Company from an employee or other service provider of the Company upon death, disability or termination of employment or service relationship, in each case, of such employee or service provider,

(ix) as part of a sale of the undersigned’s Lock-Up Securities acquired in the Public Offering (other than, in the case of an officer or director of the Company, any Securities such officer or director may purchase in the Public Offering) or in open market transactions after the closing date for the Public Offering,

(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of “net” or “cashless” exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity award granted under a stock incentive plan or other equity award plan or other arrangement, each such agreement, plan or arrangement which is described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,

(xi) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company’s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, “Change of Control” shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving entity)); provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned’s Lock-Up Securities shall remain subject to the provisions of this Letter Agreement, or

(xii) pursuant to a contract, instruction or plan that met the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) on the date such contract, instruction or plan was entered into or adopted (a “10b5-1 Plan”); provided that such 10b5-1 Plan was established prior to the execution of this Letter Agreement by the undersigned, the existence and details of such 10b5-1 Plan were communicated to the Representatives and such 10b5-1 Plan will not be amended or otherwise modified during the Restricted Period; provided, further, that any filing under Section 16(a) of the Exchange Act in connection with such transfer shall indicate, to the extent permitted by such section and the related rules and regulations, that such transfer was pursuant to a 10b5-1 Plan;

provided that (A) in the case of any transfer, disposition or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representatives a lock-up letter in the form of this Letter Agreement, (B) in the case of any transfer or distribution pursuant to clause (a) (ii), (iii), (iv), (v), (vi) and (ix), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 or any required Schedule 13F, Schedule 13G or Schedule 13G/A, in each case made after the expiration of the Restricted Period referred to above) and (C) in the case of any transfer, disposition or distribution pursuant to clause (a)(i), (vii), (viii) and (x) it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section 16(a) of the Exchange

Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature of such transfer;

(b) exercise outstanding options, settle restricted stock units or other equity awards granted pursuant to plans or other equity compensation arrangements or exercise warrants, in each case described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that any Lock-up Securities received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement;

(c) convert convertible securities or warrants to acquire shares of Common Stock into shares of Common Stock; provided that any such shares of Common Stock or warrants received upon such conversion shall be subject to the terms of this Letter Agreement; and

(d) establish one or more trading plans pursuant to Rule 10b5-1 under the Exchange Act for the transfer or disposition of shares of Lock-Up Securities; provided that (1) such plans do not provide for the transfer or disposition of Lock-Up Securities during the Restricted Period, (2) no filing or public announcement shall be made voluntarily in connection with such trading plan and (3) any required public announcement or filing under the Exchange Act made by the undersigned, the Company or any other person regarding the establishment of such trading plan during the Restricted Period shall include a statement that the undersigned is not permitted to transfer, sell or otherwise dispose of securities under such trading plan during the Restricted Period in contravention of this Letter Agreement.

The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Lock-Up Securities, in cash or otherwise.

In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.

The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.

The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representatives and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation.

This Letter Agreement shall automatically, and without any action on the part of any other party, terminate and be of no further force and effect, and the undersigned shall automatically be released from all obligations under this Letter Agreement if: (i) the Underwriting Agreement does not become effective by June 30, 2024; (ii) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder; (iii) either the Company, on the one hand, or the Representatives, on the other hand, notifies the other in writing prior to the execution of the Underwriting Agreement that it does not intend to proceed with the Public Offering; or (iv) the registration statement filed with the Securities and Exchange Commission in connection with the Public Offering is withdrawn prior to the execution of the Underwriting Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. This Letter Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g. www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York.

[Signature Page Follows]


Very truly yours,

[NAME OF STOCKHOLDER]

By:
		Name:
		Title:

EX-5.1 3 d812513dex51.htm EX-5.1 EX-5.1

Exhibit 5.1



May 22, 2024
				+1 617 526 6000 (t) +1 617 526 5000 (f) www.wilmerhale.com

Dyne Therapeutics, Inc.

1560 Trapelo Road

Waltham, MA, 02451

Re:	Dyne Therapeutics, Inc. – Registration Statement on Form S-3

Ladies and Gentlemen:

This opinion is being furnished to you in connection with (i) the Registration Statement on Form S-3 (File No. 333-277655) (the “Registration Statement”) filed by Dyne Therapeutics, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), for the registration of, among other things, shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), which may be issued from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act at an indeterminate aggregate offering price, as set forth in the Registration Statement and the base prospectus contained therein (the “Base Prospectus”), (ii) the prospectus supplement, dated May 20, 2024 (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”) and (iii) the issuance and sale by the Company pursuant to the Registration Statement of up to 12,075,000 shares of Common Stock, including up to 1,575,000 shares of Common Stock issuable upon exercise of an option to purchase additional shares granted by the Company (the “Shares”).

The Shares are to be issued and sold by the Company pursuant to an underwriting agreement, dated May 21, 2024 (the “Underwriting Agreement”), by and among the Company and Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the underwriters named therein. The Underwriting Agreement is being filed with the Commission as Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed on the date hereof.

We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares. We have examined and relied upon a signed copy of the Registration Statement and the Prospectus, each as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, minutes of meetings and actions of the stockholders and the Board of Directors of the Company, including the committees thereof, as provided to us by the Company, the Restated Certificate of Incorporation and Amended and Restated Bylaws of the Company, each as restated and/or amended to date, and such other documents, instruments and certificates as we have deemed necessary for the purposes of rendering the opinions hereinafter set forth.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents.

LOGO

Dyne Therapeutics, Inc.

May 22, 2024

Page 2

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

We hereby consent to the filing of this opinion with the Commission, in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, as an exhibit to the Current Report on Form 8-K to be filed by the Company on the date hereof in connection with the sale of the Shares and to the use of our name therein and in the Prospectus Supplement and any related prospectus supplement under the caption “Legal Matters.” In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

/S/ WILMER CUTLER PICKERING

HALE AND DORR LLP

EX-99.1 4 d812513dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $325.5 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about May 24, 2024, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. and Raymond James are acting as co-managers for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE^™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD).

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties related to the satisfaction of customary closing conditions for the public offering and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement filed with the SEC on May 20, 2024, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

Contacts:

Investors

Amy Reilly

areilly@dyne-tx.com

857-341-1203 LOGO

Media

Stacy Nartker

snartker@dyne-tx.com

781-317-1938

EX-101.SCH 5 dyn-20240521.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 dyn-20240521_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 7 dyn-20240521_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 g812513g0522055857445.jpg GRAPHIC begin 644 g812513g0522055857445.jpg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g812513g0522060047594.jpg GRAPHIC begin 644 g812513g0522060047594.jpg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end GRAPHIC 10 g812513g0522062611349.jpg GRAPHIC begin 644 g812513g0522062611349.jpg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g812513g0522062611541.jpg GRAPHIC begin 644 g812513g0522062611541.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	May 21, 2024
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001818794
Document Type	8-K
Document Period End Date	May 21, 2024
Entity Registrant Name	Dyne Therapeutics, Inc.
Entity Incorporation State Country Code	DE
Entity File Number	001-39509
Entity Tax Identification Number	36-4883909
Entity Address, Address Line One	1560 Trapelo Road
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	(781)
Local Phone Number	786-8230
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common stock, $0.0001 par value per share
Trading Symbol	DYN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d812513d8k.htm dyn-20240521.xsd dyn-20240521_lab.xml dyn-20240521_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 20 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d812513d8k.htm": { "nsprefix": "dyn", "nsuri": "http://www.dyne-tx.com/20240521", "dts": { "inline": { "local": [ "d812513d8k.htm" ] }, "schema": { "local": [ "dyn-20240521.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "dyn-20240521_lab.xml" ] }, "presentationLink": { "local": [ "dyn-20240521_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-05-21_to_2024-05-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d812513d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-05-21_to_2024-05-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d812513d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.dyne-tx.com//20240521/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 21 0001193125-24-144470-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-144470-xbrl.zip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end XML 23 d812513d8k_htm.xml IDEA: XBRL DOCUMENT 0001818794 2024-05-21 2024-05-21 false 0001818794 8-K 2024-05-21 Dyne Therapeutics, Inc. DE 001-39509 36-4883909 1560 Trapelo Road Waltham MA 02451 (781) 786-8230 false false false false Common stock, $0.0001 par value per share DYN NASDAQ true false